骨传导装置治疗单侧感音神经性聋与生活质量关联的系统综述与荟萃分析
该系统综述与荟萃分析检索1978年至2021年6月数据库,纳入11项前瞻性干预研究共203例单侧感音神经性聋成人患者,评估骨传导装置植入前后生活质量变化。结果显示听力相关生活质量(APHAB全局评分及SSQ各亚量表)显著改善,而通用生活质量(HUI-3)无显著变化。
要点
- 骨传导装置可改善成人单侧感音神经性聋患者的听力相关生活质量。
- 通用生活质量量表HUI-3评分未见显著改变。
- 需针对该人群尤其是儿童开展前瞻性生活质量研究。
核心结论
- 成人单侧感音神经性聋患者接受骨传导装置后,听力相关生活质量可能改善,但通用生活质量未见改善。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane Library和ClinicalTrials.gov从1978年1月1日至2021年6月24日。
- 纳入标准为前瞻性干预研究,单侧感音神经性聋定义:较差耳纯音平均>70 dB听力损失且较好耳≤30 dB,接受单侧骨传导装置植入,并使用验证工具评估干预前后生活质量,样本量≥10例。
- 共纳入11项研究203例患者,均为成人研究,其中10项为非随机队列研究。
主要发现
- APHAB全局评分平均变化15.50(95%CI 12.63-18.36;I2=0),有显著统计学和临床意义改善。
- SSQ听力质量亚量表平均变化1.19(95%CI 0.46-1.92;I2=78.4%),言语亚量表平均变化2.03(95%CI 1.68-2.37;I2=0),空间听觉亚量表平均变化1.51(95%CI 0.57-2.44;I2=81.1%),均显著改善。
- HUI-3平均评分变化0.03(95%CI -0.04至0.10;I2=0),无显著变化。
- 偏倚风险评为低至中等。
关键数值与推荐
- 单侧感音神经性聋定义:较差耳纯音平均>70 dB听力损失,较好耳≤30 dB。
- 主要结局为骨传导装置插入后6个月生活质量评分平均变化。
- 采用的生活质量工具包括APHAB、HUI-3和SSQ。
临床怎么用
- 对于成人单侧感音神经性聋,骨传导装置可能改善听力相关生活质量,咨询时应结合此证据。
- 通用生活质量评估可能无法反映骨传导装置带来的益处,临床评估宜采用听力相关量表。
局限性
- 纳入研究多为非随机队列研究,骨传导装置类型异质。
- 仅纳入成人研究,缺乏儿童数据。
- 部分分析存在中高度异质性(如SSQ空间听觉亚组I2=81.1%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although bone conduction devices (BCDs) have been shown to improve audiological outcomes of patients with single-sided sensorineural deafness (SSD), their effects on the patients' quality of life (QOL) are unclear. OBJECTIVE: To investigate the association of BCDs on QOL in patients with SSD. DATA SOURCES: Literature search of databases (Medline, Embase, Cochrane Library, and ClinicalTrials.gov) from January 1, 1978, to June 24, 2021, was performed. STUDY SELECTION: Prospective interventional studies with 10 or more participants with SSD (defined as pure tone average >70 dB hearing loss in the worse hearing ear and ≤30 dB in the better hearing ear) who underwent unilateral BCD implantation and assessment of QOL before and after the intervention using a validated tool were eligible for inclusion. Studies on adults and children were eligible for inclusion. Patients with only conductive, mixed, or bilateral hearing loss were excluded. DATA EXTRACTION AND SYNTHESIS: Data were extracted by 2 independent reviewers. Study clinical and demographic characteristics were obtained. Meta-analysis of mean differences in QOL scores before and after the intervention was performed. Study bias was assessed using Joanna Briggs Institute risk of bias tool. MAIN OUTCOMES AND MEASURES: The main study outcome was mean change in QOL scores at 6 months after insertion of BCDs. The 3 QOL instruments used in the studies included the Abbreviated Profile of Hearing Aid Benefit (APHAB), the Health Utilities Index-3 (HUI-3), and the Speech, Spatial and Qualities of Hearing Scale (SSQ). The APHAB and the SSQ are the hearing-related QOL measures, whereas the HUI-3 is a generic QOL measure. RESULTS: A total of 486 articles were identified, and 11 studies with 203 patients met the inclusion criteria. Only adult studies met inclusion criteria. Ten of 11 studies were nonrandomized cohort studies. The BCDs assessed were heterogeneous. There was a significant statistical and clinically meaningful improvement in the global APHAB scores (mean change, 15.50; 95% CI, 12.63-18.36; I2 = 0) and the SSQ hearing qualities (mean change, 1.19; 95% CI, 0.46-1.92; I2 = 78.4%), speech (mean change, 2.03; 95% CI, 1.68-2.37; I2 = 0), and spatial hearing (mean change, 1.51; 95% CI, 0.57-2.44; I2 = 81.1%) subscales. There was no significant change detected in the mean HUI-3 scores (mean change, 0.03; 95% CI, -0.04 to 0.10; I2 = 0). The risk of bias was assessed to be low to moderate. CONCLUSIONS AND RELEVANCE: These findings suggest that adult patients who receive BCDs may experience improvements in hearing-specific QOL measures but not in generic QOL measures. Prospective QOL studies should be considered in this cohort, particularly for children with SSD.
引用
- Hampton T, Milinis K, Whitehall E, et al. Association of Bone Conduction Devices for Single-Sided Sensorineural Deafness With Quality of Life: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 34647990. doi:10.1001/jamaoto.2021.2769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。